• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Windtree Therapeutics Inc. (Amendment)

    5/17/23 7:30:26 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email
    SC 13D/A 1 d254317dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Windtree Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    97382D204

    (CUSIP Number)

    James Huang

    Panacea Venture

    No. 5, Lane 1350, Fuxing Middle Road

    Xuhui District, Shanghai

    China 200031

    (86-21) 6176-1101

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 17, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 97382D204   13D   Page 1 of 8 pages

     

      1    

      Names of Reporting Persons

     

      Panacea Venture Healthcare Fund I, L.P.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      Sole Voting Power

     

      0

         8  

      Shared Voting Power

     

      68,984

         9  

      Sole Dispositive Power

     

      0

       10  

      Shared Dispositive Power

     

      68,984

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      68,984

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      1.3%

    14  

      Type of Reporting Person

     

      PN


    CUSIP No. 97382D204   13D   Page 2 of 8 pages

     

      1    

      Names of Reporting Persons

     

      Panacea Venture Healthcare Fund GP I, L.P.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      Sole Voting Power

     

      0

         8  

      Shared Voting Power

     

      68,984

         9  

      Sole Dispositive Power

     

      0

       10  

      Shared Dispositive Power

     

      68,984

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      68,984

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      1.3%

    14  

      Type of Reporting Person

     

      PN


    CUSIP No. 97382D204   13D   Page 3 of 8 pages

     

      1    

      Names of Reporting Persons

     

      Panacea Venture Healthcare Fund GP Company, Ltd.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      Sole Voting Power

     

      0

         8  

      Shared Voting Power

     

      68,984

         9  

      Sole Dispositive Power

     

      0

       10  

      Shared Dispositive Power

     

      68,984

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      68,984

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      1.3%

    14  

      Type of Reporting Person

     

      CO


    CUSIP No. 97382D204   13D   Page 4 of 8 pages

     

      1    

      Names of Reporting Persons

     

      Panacea Venture Management Company Ltd.

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      Sole Voting Power

     

      0

         8  

      Shared Voting Power

     

      68,984

         9  

      Sole Dispositive Power

     

      0

       10  

      Shared Dispositive Power

     

      68,984

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      68,984

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      1.3%

    14  

      Type of Reporting Person

     

      CO


    CUSIP No. 97382D204   13D   Page 5 of 8 pages

     

      1    

      Names of Reporting Persons

     

      James Huang

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Republic of China

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      Sole Voting Power

     

      6,625

         8  

      Shared Voting Power

     

      68,984

         9  

      Sole Dispositive Power

     

      6,625

       10  

      Shared Dispositive Power

     

      68,984

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      75,609

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      1.5%

    14  

      Type of Reporting Person

     

      IN


    CUSIP No. 97382D204   13D   Page 6 of 8 pages

     

    Explanatory Note

    This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on December 31, 2018 (as amended to date, the “Schedule 13D”), relating to the common stock, par value $0.001 per share (the “Common Stock”), of Windtree Therapeutics, Inc. (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

      (e)

    – (b)

    The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of the date hereof, based upon 5,147,919 shares of Common Stock outstanding as of April 27, 2023.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole power
    to vote or to
    direct the
    vote:
         Shared power
    to vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Panacea Venture Healthcare Fund I, L.P.

         68,984        1.3 %      0        68,984        0        68,984  

    Panacea Venture Healthcare Fund GP I, L.P.

         68,984        1.3 %      0        68,984        0        68,984  

    Panacea Venture Healthcare Fund GP Company, Ltd.

         68,984        1.3 %      0        68,984        0        68,984  

    Panacea Venture Management Company Ltd.

         68,984        1.3 %      0        68,984        0        68,984  

    James Huang

         75,609        1.5 %      6,625        68,984        6,625        68,984  

    Panacea Venture Healthcare Fund I, L.P. is the holder of 68,984 shares of Common Stock. Panacea Venture Management Company Ltd. is the management company of Panacea Venture Healthcare Fund GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund GP I, L.P., which is the general partner of Panacea Venture Healthcare Fund I, L.P. By virtue of his control of Panacea Venture Management Company Ltd., Mr. Huang may be deemed to share beneficial ownership of the securities held by Panacea Venture Healthcare Fund I, L.P.

    In addition, Mr. Huang also holds 5,825 shares of Common Stock and options to purchase 800 shares of Common stock that are currently exercisable.


    CUSIP No. 97382D204   13D   Page 7 of 8 pages

     

    (c)

    None.

     

    (d)

    None.

     

    (e)

    This Amendment No. 4 is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own more than five percent of the Common Stock.


    CUSIP No. 97382D204   13D   Page 8 of 8 pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: May 17, 2023

     

    Panacea Venture Healthcare Fund I, L.P.
    By: Panacea Venture Healthcare Fund GP I, L.P., its general partner
    By: Panacea Venture Healthcare Fund GP Company, Ltd., its general partner
    By: Panacea Venture Management Company Ltd., its manager

    By:

     

    /s/ James Huang

    Name:

     

    James Huang

    Title:

     

    Founding Managing Partner

    Panacea Venture Healthcare Fund GP I, L.P.

    By: Panacea Venture Healthcare Fund GP Company, Ltd., its general partner
    By: Panacea Venture Management Company Ltd., its manager

    By:

     

    /s/ James Huang

    Name:

     

    James Huang

    Title:

     

    Founding Managing Partner

    Panacea Venture Healthcare Fund GP Company, Ltd.
    By: Panacea Venture Management Company Ltd., its manager

    By:

     

    /s/ James Huang

    Name:

     

    James Huang

    Title:

     

    Founding Managing Partner

    Panacea Venture Management Company Ltd.

    By:

     

    /s/ James Huang

    Name:

     

    James Huang

    Title:

     

    Founding Managing Partner

    James Huang

    /s/ James Huang

    Get the next $WINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Windtree Announces Plan for Cryptocurrency Treasury Policy

      WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, announced that its Board of Directors has agreed that the Company will create a cryptocurrency policy that will allow the Company to accept cryptocurrency as an option for payment and also allow the Company to hold the cryptocurrency as an asset. The Company's cryptocurrency policy is intended to align with innovative digital commerce trends where millions of people hold cryptocurrency. If a payment

      6/3/25 4:05:00 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

      Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study (the "SEISMiC C Study") for J

      5/22/25 8:16:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

      WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced istaroxime data from the early cardiogenic shock SEISMiC Extension Phase 2b study will be presented today at the European Society of Cardiology Heart Failure 2025 Conference in Belgrade, Serbia. The istaroxime data will be presented by Jan Biegus MD, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland. The presentation is entitled, "Safety and Efficacy of up to 60

      5/19/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kelly Leanne

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      1/14/25 4:17:38 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      8/14/24 4:24:25 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $WINT
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 7:15:44 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Windtree Therapeutics Inc.

      SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 3:40:27 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 8:53:39 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

      Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/4/21 6:09:49 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-1 filed by Windtree Therapeutics Inc.

      S-1 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      5/16/25 4:10:33 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      5/16/25 8:18:18 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Windtree Therapeutics Inc.

      10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      5/15/25 5:21:34 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/28/23 7:24:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/27/23 7:34:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Financials

    Live finance-specific insights

    See more
    • Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive

      5/16/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

      4/15/25 8:00:00 AM ET
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $WINT
    Leadership Updates

    Live Leadership Updates

    See more
    • Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

      WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w

      1/13/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Leadership Transition Plan With Industry Veterans

      WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser

      11/14/24 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates. "The second quarter of 2024 was marked with significant progress with our lead asset, istaroxime in development for the treatment of cardiogenic shock. We expect the istaroxime Phase 2 SEISMiC Extension study to complete enrollment in the next few weeks and we plan to report topline data by the end of the third quarter of 2024. We are also sup

      8/20/24 4:05:00 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care